Termination of acute-phase response: Role of some cytokines and anti-inflammatory drugs

General Pharmacology

Volumn 31, Issue 1, 1998, Pages 9-18

  Koj, Aleksander ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Acute phase; Anti inflammatory cytokines; IL 1 receptor antagonist; IL 10; IL 13; IL 4; Inhibition of cytokine synthesis; Nonsteroidal anti inflammatory ddrugs; Pyridinyl imidazoles; Soluble cytokine receptors; TGF

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; ACUTE PHASE PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; GLUCOCORTICOID; INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; PENTOXIFYLLINE; PIROXICAM; ROLIPRAM; ROOPEROL; SALICYLIC ACID DERIVATIVE; TENIDAP; TETRAHYDROPAPAVEROLINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE PHASE RESPONSE; ANTIINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG ACTIVITY; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0032127397     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(97)00435-7     Document Type: Review

References (137)

1. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev. 7:1996;231-240.
2. Allison A.C., Eugui E.M. Co-ordinate inhibition of the production of TNF, IL-1, and IL-6 by small molecules. Ann. NY Acad. Sci. 762:1995;331-341.
3. Amano Y., Lee S.W., Allison A.C. Inhibition by glucocorticoids of the formation of interleukin-1α, interleukin-1β, and interleukin-6. mediation by decreased mRNA stability Molec. Pharmac. 43:1993;176-182.
4. Autissier P., Liautard J., Brochier J., Gaillard J.P. Activation of the gp130 signaling pathway by monoclonal antibodies directed against gp130 molecule. Eur. J. Immunol. 27:1997;794-797.
5. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., Griswold D.E. Pharmaceutical profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmac. Exp. Ther. 279:1996;1453-1461.
6. Barnes P.J., Adcock I. Antiinflammatory actions of steroids. molecular mechanisms Trends Pharmac. Sci. 14:1993;436-441.
7. Barton B.E. The biological effects of interleukin 6. Medicinal Res. Rev. 16:1996;87-109.
8. Baumann H., Gauldie J. The acute phase response. Immunol. Today. 15:1994;74-80.
9. Baumann H., Wang Y., Morella K.K., Lai C.F., Dams H., Hilton D.J., Hawley R.G., Mackiewicz A. Complex of the soluble IL-11 receptor and IL-11 acts as IL-6-type cytokine in hepatic and nonhepatic cells. J. Immnol. 157:1996;284-290.
10. Bereta J., Bereta M., Allison A.C., Kruger P.B., Koj A. Inhibitory effect of dicatechol rooperol on VCAM-1 and iNOS expression in cytokine stimulated endothelium. Life Sci. 60:1997;325-334.
11. Bernard C., Barnier P., Merval R., Esposito B., Tedgui A. Petoxifylline selectively inhibits tumor necrosis factor synthesis in the arterial wall. J. Cardiovasc. Pharmac. 25(Suppl. 2):1995;S30-S33.
12. Blackburn W.D., Prupas H.M., Silverfield J.C., Poiley J.E., Caldwell J.R., Collins R.L., Miller M.J., Sikes D.H., Kaplan H., Fleischmann R., Scoville C.D., Rutstein J.E., Hurd E.R., Louie J.S., Bankhurst A.D., Weaver A.L., Sebba A.I., Appelrouth D.J., Hudson N.P., Gordon G.V., Gordon R.D., Ludivico C.L., Austin M.C., Sanders K.M., Schuette P.T., Moidel R.A., Kraska A.R., Ting N., Shanahan W.R., Loose L.D. Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone. Arthr. Rheum. 38:1995;1447-1456.
13. Bondeson J. Effects of tenidap on intracellular signal transduction and the induction of proinflammatory cytokines. a review Gen. Pharmac. 27:1996;943-956.
14. Bondeson J., Sundler R. Differential effects of tenidap on the zymosan- and lipopolysaccharide-induced expression of mRNA for proinflammatory cytokines in macrophages. Biochem. Pharmac. 52:1996;35-42.
15. Brown C.Y., Lagnado C.A., Vadas M.A., Goodall G.J. Differential regulation of the stability of cytokine mRNAs in lipopolysaccharide-activated blood monocytes in response to interleukin-10. J. Biol. Chem. 271:1996;20108-20112.
16. Brattsand R., Linden M. Cytokine modulation by glucocorticoids. mechanisms and actions in cellular studies Aliment. Pharmac. Ther. 10(Suppl. 2):1996;81-90.
17. Broxmeijer H.E., Lu L., Cooper S., Rubin B.Y., Gillis S., Williams D.E. Synergistic effects of purified recombinant human and murine B-cell growth factor/IL-4 on colony formation in vitro by hematopoietic progenitor cells. J. Immunol. 141:1988;3852-3862.
18. Calandra T., Bucala R. Macrophage migration inhibitory factor (Mif). a glucocorticoid counter-regulator within the immune system Crit. Rev. Immunol. 17:1997;77-88.
19. Campos S.P., Wang Y., Koj A., Baumann H. Divergent transforming growth factor-β effects on IL-6 regulation of acute phase plasma proteins in rat hepatoma cells. J. Immunol. 151:1993;7128-7137.
20. Capsoni F., Minonzio F., Ongari A.M., Carbonelli V., Galli A., Zanussi C. Interleukin-10 down-regulates oxidative metabolism and antibody-dependent cellular cytotoxicity of human neutrophils. Scand. J. Immunol. 45:1997;269-275.
21. Cassatella M.A. The production of cytokines by polymorphonuclear neutrophils. Immunol. Today. 16:1995;21-26.
22. Chadban S.J., Tesch G.H., Foti R., Atkins R.C., Nikolic-Paterson D.J. Interleukin-10 is a mesangial cell growth factor in vitro and in vivo. Lab. Invest. 76:1997;619-627.
23. Colotta F., Dower S.K., Sims J.E., Mantovani A. The type II "decoy" receptor. a novel regulatory pathway for interleukin-1 Immunol. Today. 15:1994;562-565.
24. Cuenda A., Cohen P., Buee-Scherrer V., Goedert M. Activation of stress-activated protein kinase-3 (Sapk3) by cytokines and cellular stresses is mediated via SAPKK3 (Mkk6); comparison of the specificities of SAPK3 and SAPK2 (RK/p38). EMBO J. 16:1997;295-305.
25. Daftarian P.M., Kumar A., Kryworuchko M., Diaz-Mitoma F. IL-10 production is enhanced in human T cells by IL-12 and IL-6 and in monocytes by tumor necrosis factor-α J. Immunol. 157:1996;12-20.
26. Davis R.J. Mapks. new JNK expands the group TIBS. 19:1995;470-473.
27. Dayer J.M., Burger D. Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur. Cytokine Networks. 5:1994;563-571.
28. Debets R., Savelkoul H.F.J. Cytokines as cellular communicators. Mediat. Inflamm. 5:1996;417-423.
29. Derocq J.M., Segui M., Chazel-Poinot C., Minty A., Caput D., Ferrara P., Casellas P. Interleukin-13 stimulates interleukin-6 production by human keratinocytes. Similarity with interleukin-4. FEBS Lett. 343:1994;32-36.
30. De Vries J.E. Immunosuppressive and antiinflammatory properties of interleukin 10. Ann. Med. 27:1995;537-541.
31. Dhellencourt C.L., Diaw L., Cornillet P., Guenounou Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta and IL-10 by petoxifylline. Int. J. Immunopharmac. 18:1996;739-748.
32. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood. 87:1996;2095-2147.
33. Dolganov G., Bort S., Lovett M., Burr J., Schubert L., Short D., McGurn M., Gibson C., Lewis D.B. Coexpression of the interleukin-13 and interleukin-4 genes correlates with their physical linkage in the cytokine gene cluster on human chromosome 5q23-31. Blood. 87:1996;3316-3326.
34. Doughty L.A., Patrene K.D., Evans C.H., Boggs S.S., Robbins P.D. Constitutive systemic expression of IL-1Ra or soluble TNF receptor by genetically modified hematopoietic cells suppresses LPS induction of IL-6 and IL-10. Gene Ther. 4:1997;252-257.
35. Engelhardt G., Bogel R., Schnitzer C., Utzmann R. Meloxicam. influence on arachidonic acid metabolism. Part 1. In vitro findings Biochem. Pharmac. 51:1996;21-28.
36. Eppinger M.J., Ward P.A., Bolling S.F., Deeb G.M. Regulatory effects of interleukin-10 on lung ischemia-reperfusion injury. J. Thorac. Cardiovasc. Surg. 112:1996;1301-1305.
37. Evans C.H., Robbins P.D. The interleukin-1 receptor antagonist and its delivery by gene transfer [review]. Receptor. 4:1994;9-15.
38. Fanslow W.C., Clifford K., VandenBos T., Teel A., Armitage R.J., Beckmann M.P. A soluble form of the interleukin-4 receptor in biological fluids. Cytokine. 2:1990;398-401.
39. Fernandez-Botran R., Chilton P.M., Ma Y. Soluble cytokine receptors. their roles in immunoregulation, disease and therapy Adv. Immunol. 63:1996;269-336.
40. Fiebiech B.L., Lieb K., Hull M., Berger M., Bauer J. Effect of NSAIDs on IL-1β-induced IL-6 mRNA and protein synthesis in human astrocytoma cells. Neuroreport. 7:1996;1209-1213.
41. Frolich J.C. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmac. Sci. 18:1997;30-34.
42. Fushimi T., Okayama H., Seki T., Shimura S., Shirato K. Dexamethasone suppressed gene expression and production of interleukin-10 by human peripheral blood mononuclear cells and monocytes. Allerg. Immunol. 112:1997;13-18.
43. Gastl G.A., Abrams J.S., Nanus D.M., Oosterkamp R., Silver J., Liu F., Chen M., Albino A.P., Bander N.H. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int. J. Cancer. 55:1993;96-101.
44. Glauser M.P. The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock. Drugs. 6(Suppl. 2):1996;9-17.
45. Grande J.P. Role of transforming growth factor-β in tissue injury and repair. Proc. Soc. Exp. Biol. Med. 214:1997;27-40.
46. Grunig G., Corry D.B., Leach M.W., Seymour B.W.P., Kurup V.P., Rennick D.M. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J. Exp. Med. 185:1997;1089-1099.
47. Guzdek A., Niżankowska E., Allison A.C., Kruger P.B., Koj A. Cytokine production in human and rat macrophages and dicatechol rooperol and esters. Biochem. Pharmac. 52:1996;991-998.
48. Guzdek A., Turyna B., Allison A.C., Sladek K., Koj A. Rooperol, an inhibitor of cytokine synthesis, decreases the respiratory burst in human and rat leukocytes and macrophages. Mediat. Inflamm. 6:1997;53-57.
49. Guzdek A., Rokita H., Cichy J., Allison A. C. and Koj A. (in press) Rooperol tetraacetate decreases cytokine mRNA levels and binding capacity of transcription factors in U937 cells. Mediat. Inflamm.
50. Han J., Thompson P., Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med. 172:1990;391-394.
51. Han J., Lee J.D., Bibb S.L., Ulevitch R.J. A MAP kinase targeted by endotoxin in mammalian cells. Science. 265:1994;808-811.
52. Harrison P., Downs T., Friese P., Wolf R., George J.N., Burstein S.A. Inhibition of the acute-phase response in vivo by anti-gp130 monoclonal antibodies. Br. J. Haematol. 95:1996;443-451.
53. Hauptmann B., Van Damme J., Dayer J.M. Modulation of IL-1 inflammatory and immunomodulatory properties by IL-6. Eur. Cytokine Networks. 2:1991;39-48.
54. Heinrich P.C., Castell J.V., Andus T. Interleukin 6 and the acute phase response. Biochem. J. 265:1990;621-636.
55. Howard M., O'Garra A., Ishida H., De Waal Malefyt R., De Vries J. Biological properties of interleukin 10. J. Clin. Immunol. 12:1992;239-247.
56. Hu-Li J., Shevach E.M., Mizuguchi J., Ohara J., Mosmann T., Paul W.E. B cell stimulatory factor-1 (interleukin-4) is a potent costimulant for normal resting T lymphocytes. J. Exp. Med. 165:1987;157-172.
57. Ihle J.N., Witthuhn B.A., Quelle F.W., Yamamoto K., Silvennoinen O. Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol. 13:1995;369-398.
58. Ishizaka S., Saito S., Yoshikawa M., Kimoto M., Nishiyama T. IL-10 production in mouse hepatocytes augmented by TGF-beta. Cytokine. 8:1996;837-843.
59. Isomaki P., Luukkainen R., Saario R., Toivanen P., Punnonen J. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthrit. Rheum. 39:1996;386-395.
60. Jenkins J.K., Malyak M., Arend W.P. The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1β production in human monocytes and neutrophils. Lymphokine Cytokine Res. 13:1994;47-54.
61. Joosten L.A.B., Lubberts E., Durez P., Helsen M.M.A., Jacobs M.J.M., Goldman M., van den Berg W.B. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Arthrit. Rheum. 40:1997;249-260.
62. Joyce D.A., Gibbons D.P., Gren P., Steer J.H., Feldmann M., Brennan F.M. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur. J. Immunol. 24:1994;2699-2705.
63. Joyce D.A., Steer J.H., Kloda A. Dexamethasone antagonizes IL-4 and IL-10-induced release of IL-1Ra by monocytes but augments IL-4-, IL-10- and TGF-β-induced suppression of TNF-α release. J. Interferon Cytokine Res. 16:1996;511-517.
64. Karres I., Kremer J.P., Steckholzer U., Kenney J.S., Ertel W. Transforming growth factor-β1 inhibits synthesis of cytokines in endotoxin-stimulated human whole blood. Arch. Surg. 131:1996;1310-1317.
65. Kishimoto T., Akira S., Narazak M., Taga T. Interleukin-6 family of cytokines and gp130. Blood. 86:1995;1243-1251.
66. Koj A. The role of interleukin-6 as the hepatocyte stimulating factor in the network of inflammatory cytokines. Ann. NY Acad. Sci. 557:1989;1-6.
67. Koj A. Initiation of acute phase response and synthesis of cytokines. Biochim. Biophys. Acta. 1317:1996;84-94.
68. Koj A., Gauldie J. and Baumann H. (1993) Biological perspectives of cytokine and hormone networks. In Acute Phase Proteins. Molecular Biology, Biochemistry and Clinical Applications, Vol. 1 (Edited by Mackiewicz A., Kushner I. and Baumann H. ), pp. 275-287. CRC Press, Boca Raton, FL.
69. Kopp E., Ghosh S. Inhibition of NFκB by sodium salicylate and aspirin. Science. 265:1994;956-959.
70. Kuga S., Otsuka T., Niiro H., Nunoi H., Nemoto Y., Nakano T., Ogo T., Umei T., Niho Y. Suppression of superoxide anion production by interleukin-10 is accompanied by a downregulation of the genes for subunit proteins of NADPH oxidase. Exp. Hematol. 24:1996;151-157.
71. Kulkarni A.B., Karlsson S. Transforming growth factor-β1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am. J. Pathol. 143:1993;3-9.
72. Kushner I. The phenomenon of the acute phase response. Ann. NY Acad. Sci. 389:1982;39-48.
73. Lai C.F., Ripperger J., Morella K.K., Jurlander J., Hawley T.S., Carson W.E., Kordula T., Caligiuri M.A., Hawley R.G., Fey G.H., Baumann H. Receptors for interleukin (Il)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. J. Biol. Chem. 271:1996;13968-13975.
74. Laichalk L.L., Danforth J.M., Standiford T.J. Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. FEMS Immunol. Med. Microbiol. 15:1996;181-187.
75. Lee J.C., Badger A.M., Griswold D.E., Dunnington D., Truneh A., Votta B., White J.R., Young P.R., Bender P.E. Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors. Ann. NY Acad. Sci. 696:1993;149-170.
76. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., McNulty D., Blumenthal M.J., Heys J.R., Landvatter S.V., Strickler J.E., McLaughlin M.M., Siemens I.R., Fisher S.M., Livi G.P., White J.R., Adams J.L., Young P.R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 372:1994;739-746.
77. Lee J.C., Young P.R. Role of CSBP/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J. Leukocyte Biol. 59:1996;152-157.
78. Lemaire I., Ouellet S. Role of transforming growth factor-β1 in down-regulating TNF production by alveolar macrophages during asbestos-induced pulmonary fibrosis. Mediat. Inflamm. 5:1996;37-42.
79. Liu Y., Wei S.H.Y., Ho A.S.Y., de Waal Malefyt R., Moore K.W. Expression cloning and characterization of a human IL-10 receptor. J. Immunol. 152:1994;1821-1829.
80. Loyer P., Ilyin G., Razzak Z.A., Banchereau J., Dezier J.F., Campion J.P., Guguen-Guillouzo C., Guillouzo A. Interleukin 4 inhibits the production of some acute-phase proteins by human hepatocytes in primary culture. FEBS Lett. 336:1993;215-220.
81. Mackiewicz A., Ganapathi M.K., Schultz D., Brabenec A., Kushner I. Transforming growth factor-β1 regulates synthesis of acute phase proteins. Proc. Natl. Acad. Sci. USA. 87:1990;1491-1495.
82. Mackiewicz A., Wiznerowicz M., Roeb E., Karczewska A., Nowak J., Heinrich P.C., Rose-John S. Soluble interleukin-6 receptor is biologically active in vivo. Cytokine. 7:1995;142-149.
83. Maini R.N., Elliott M.J., Brennan F.M., Feldmann M. Beneficial effects of tumor necrosis factor-alpha (Tnf-α) blockade in rheumatoid arthritis (Ra). Clin. Exp. Immunol. 101:1995;207-212.
84. Marie C., Pitton C., Fitting C., Cavaillon J.M. Regulation by anti-inflammatory cytokines (Il-4, il-10, il-13, tgfβ) of interleukin-8 production by LPS and/or TNFα-activated human polymorphonuclear cells. Mediat. Inflamm. 5:1996;334-340. a.
85. Marie C., Pitton C., Fitting C., Cavaillon J.M. IL-10 and IL-4 synergize with TNF-α to induce IL-1Ra production by human neutrophils. Cytokine. 8:1996;147-151. b.
86. Masferrer J.L., Zweifel B.S., Seibert K., Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J. Clin. Invest. 86:1990;1375-1379.
87. Matsukawa A., Yoshimura T., Miyamoto K., Ohkawara S., Yoshinaga M. Analysis of the inflammatory cytokine network among TNFα, IL-1β, IL-1 receptor antagonist, and IL-8 in LPS-induced rabbit arthritis. Lab. Invest. 76:1997;629-638.
88. McNiff P.A., Svensson L., Pazoles C.J., Gabel C.A. Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. I. Mechanism and evidence of functional significance. J. Immunol. 153:1994;2180-2193.
89. McNiff P.A., Laliberte R.E., Svensson L., Pazoles C.J., Gabel C.A. Inhibition of cytokine activation processes in vitro by tenidap, a novel antiinflammatory agent. Cytokine. 7:1995;196-208.
90. Mertz J.M., DeWitt D.L., Stetler-Stevenson W.G., Wahl L.M. Interleukin 10 suppression of monocyte prostaglandin H synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. J. Biol. Chem. 269:1994;21322-21329.
91. Mijatovic T., Kruys V., Caput D., Defrance P., Huez G. Interleukin-4 and -13 inhibit tumor necrosis factor-alpha mRNA translational activation in lipopolysaccharide-induced mouse macrophages. J. Biol. Chem. 272:1997;14394-14398.
92. Miloux B., Laurent P., Bonnin O., Lupker J., Caput D., Vita N., Ferrara P. Cloning of the human IL-13Rα1 chain and reconstitution with the IL-4Rα of a functional IL-4/IL-13 receptor complex. FEBS Lett. 401:1997;163-166.
93. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., Vane J.R. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA. 90:1993;11693-11697.
94. Minty A., Chalon P., Derocq J.M., Dumont X., Guillemot J.C., Kaghad M., Labit C., Leplatois P., Liauzun P., Miloux B., Minty C., Casellas P., Loison G., Lupker J., Shire D., Ferrara P., Caput D. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature. 362:1993;248-250.
95. Miyajima A., Kitamura T., Harada N., Yokota T., Arai K. Cytokine receptors and signal transduction. Annu. Rev. Immunol. 10:1992;295-331.
96. Miller B.E., Krasney P.A., Gauvin D.M., Holbrook K.B., Koonz D.J., Abruzzese R.V., Miller R.E., Pagani K.A., Dolle R.E., Ator M.A., Gilman S.C. Inhibition of mature IL-1β production in murine macrophages and a murine model of inflammation by WIN 67694, an inhibitor of IL-1β converting enzyme. J. Immunol. 154:1995;1331-1338.
97. Moore K.V., O'Garra A., De Waal Malefyt R., Vieira P., Mosmann T.R. Interleukin-10. Annu. Rev. Immunol. 11:1993;165-190.
98. Mori N., Shirakawa F., Murakami S., Oda S., Eto S. Inhibitory effect of interleukin 4 on production of interleukin 6 by adult T-cell leukemia cells. Cancer Res. 53:1993;4643-4647.
99. Muchamuel T., Menon S., Pisacane P., Howard M.C., Cockayane D.A. IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia-correlation with down-modulation of TNF-alpha, IFN-gamma and IL-12 production. J. Immunol. 158:1997;2898-2903.
100. Murata T., Puri R.K. Comparison of IL-13 and IL-4-induced signaling in EBV-immortalized human B-cells. Cell. Immunol. 175:1997;33-40.
101. Niculescu R., Bradford H.N., Colman R.W., Kalf G.F. Inhibition of the conversion of pre-interleukins 1α and 1β to mature cytokines by p-benzoquinone, a metabolite of benzene. Chem. Biol. Interactions. 98:1995;211-222.
102. Niggemann B., Zuberbier T., Herz U., Enssle K., Wahn U., Renz H. Interleukin-4 (Il-4) enhances and soluble interleukin-4 receptor (sIL-4R) inhibits histamine release from peripheral blood basophils and mast cells in vitro and in vivo. Mediat. Inflamm. 6:1997;111-118.
103. Oeth P., Mackman N. Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the tissue factor gene in human monocytic cells. Blood. 86:1995;4144-4152.
104. Okuda Y., Sakoda S., Fujimura H., Yanagihara T. Pentoxifylline delays the onset of experimental allergic encephalomyelitis in mice by modulating cytokine production in peripheral blood mononuclear cells. Immunopharmacology. 35:1996;141-148.
105. Osnes L.T.N., Foss K.B., Joo G.B., Okkenhaug C., Westvik A.B., Ovstebo R., Kierulf P. Acetylsalicylic acid and sodium salicylate inhibit LPS-induced NF-κB/cRel nuclear translocation, and synthesis of tissue factor (Tf) and tumor necrosis factor alfa (Tnfα) in human monocytes. Thromb. Haemost. 76:1996;970-976.
106. Oswald I.P., Gazzinelli R.T., Sher A., James S.L. IL-10 synergizes with IL-4 and transforming growth factor-β to inhibit macrophage cytotoxic activity. J. Immunol. 148:1992;3578-3582.
107. Radomski M.W., Palmer R.M.J., Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc. Natl. Acad. Sci. USA. 87:1990;10043-10047.
108. Raingeaud J., Gupta S., Rogers J.S., Dickens M., Han J., Ulevitch R.J., Davis R.J. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 270:1995;7420-7426.
109. Rauschmayr T., Groves R.W., Kupper T.S. Keratinocyte expression of the type 2 interleukin 1 receptor mediates local and specific inhibition of interleukin 1-mediated inflammation. Proc. Natl. Acad. Sci. USA. 94:1997;5814-5819.
110. Ray A., Zhang D.H., Siegel M.D., Ray P. Regulation of interleukin-6 gene expression by steroids. Ann. NY Acad. Sci. 762:1995;79-87.
111. Rokita H., Bereta J., Koj A., Gordon A.H., Gauldie J. Epidermal growth factor and transforming growth factor-β differently modulate the acute phase response elicited by interleukin-6 in cultured liver cells from man, rat and mouse. Comp. Biochem. Physiol. 95A:1990;41-45.
112. Rokita H., Kosz-Vnenchak M., Stalińska K., Stachura J. Interleukin 1 receptor antagonist localization exclusively in non-parenchymal cells of the mouse liver. Cytokine. 9:1997;249-253.
113. Rose-John S., Heinrich P.C. Soluble receptors for cytokines and growth factors. generation and biological function Biochem. J. 300:1994;281-290.
114. Roth I., Corry D.B., Locksley R.M., Abrams S.J., Litton M.J., Fisher S.J. Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10. J. Exp. Med. 184:1996;539-548.
115. Rouse J., Cohen P., Trigon S., Morange S., Alonso-Liamazares A., Zamanillo D., Hunt T., Nebreda A.R. Identification of a novel protein kinase cascade stimulated by chemical stress and heat shock which activates MAP kinase-activated protein MAPKAP kinase-2 and induces phosphorylation of the small heat shock proteins. Cell. 78:1994;1027-1037.
116. Sakurada S., Kato T., Okamoto T. Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. Int. Immunol. 8:1996;1483-1493.
117. Schindler R., Mancilla J., Endres S., Ghorbani R., Clark S.C., Dinarello C.A. Correlations and interactions in the production of interleukin-6 (Il-6), IL-1, and tumor necrosis factor (Tnf) in human blood mononuclear cells. IL-6 suppresses IL-1 and TNF Blood. 75:1990;40-46.
118. Schreck R., Albermann K., Bauerle P.A. Nuclear factor κB. an oxidative stress-responsive transcription factor of eukaryotic cells (a review) Free Rad. Res. Comms. 17:1992;221-237.
119. Sehgal P.B. Interleukin-6-type cytokines in vivo. regulated bioavailability Proc. Soc. Exp. Biol. Med. 213:1996;238-247.
120. Siegmund B., Eigler A., Moeller J., Greten T.F., Hartmann G., Endres S. Suppression of tumor necrosis factor-α by interleukin-10 is enhanced by c-AMP elevating agents. Eur. J. Pharmac. 321:1997;231-239.
121. Smith C.A., Farrah T., Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins. activation, costimulation and death Cell. 76:1994;959-962.
122. Sporn M.B., Roberts A.B. Tgf-β problems and prospects Cell Regul. 1:1990;875-882.
123. Suzuki Y.J., Mizumo M., Packer L. Signal transduction for nuclear factor κB activation. Proposed localization of antioxidant-inhibitable step. J. Immunol. 153:1994;5008-5015.
124. Symons J.A., Young P.R., Duff G.W. Soluble type II interleukin-1 (Il-1) receptor binds and blocks processing of IL-1β precursor and loses affinity for IL-1 receptor antagonist. Proc. Natl. Acad. Sci. USA. 92:1995;1714-1718.
125. Teixeira M.M., Gristwood R.W., Cooper N., Hellewell P.G. Phosphodiesterase (Pde)4 inhibitors. antiinflammatory drugs of the future? Trends Pharmac. Sci. 18:1997;164-170.
126. Tilg H. New insights into the mechanisms of interferon alfa. an immunoregulatory and anti-inflammatory cytokine Gastroenterology. 112:1997;1017-1021.
127. Tilg H., Trehu E., Atkins M.B., Dinarello C.A., Mier J.W. Interleukin-6 (Il-6) as an antiinflammatory cytokine. induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55 Blood. 83:1994;113-117.
128. Tong L., Pav S., White D.M., Rogers S., Crane C.M., Cywin C.L., Brown M.L., Pargellis C.A. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nature Struct. Biol. 4:1997;311-316.
129. Utsunomiya I., Nagai S., Oh-ishi S. Differential effects of indomethacin and dexamethasone on cytokine production in carrageenin-induced rat pleurisy. Eur. J. Pharmac. 252:1994;213-218.
130. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. 231:1971;232-235.
131. Wahl S.M., McCartney-Francis N., Mergenhagen S.E. Inflammatory and immunomodulatory roles of TGF-β Immunol. Today. 10:1989;258-261.
132. Wang P., Wu P., Siegel M.I., Egan R.W., Billah M.M. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J. Immunol. 153:1994;811-816.
133. Wanidworanun C., Strober W. Predominant role of tumor necrosis factor-α in human monocyte IL-10 synthesis. J. Immunol. 151:1993;6853-6861.
134. Yamamoto N., Sakai F., Yamazaki H., Nakahara K., Okuhara M. Effect of FR 167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation. Eur. J. Pharmac. 314:1996;137-142.
135. Young P.R., McLaughlin M.M., Kumar S., Kassis S., Doyle M.L., McNulty D., Gallagher T.F., Fisher S., McDonnell P.C., Carr S.A., Huddleston M.J., Seibel G., Porter T.G., Livi G.P., Adams J.L., Lee J.C. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J. Biol. Chem. 272:1997;12116-12121.
136. Yue F.Y., Dummer R., Geertsen R., Hofbauer G., Laine E., Manolio S., Burg G. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int. J. Cancer. 71:1997;630-637.
137. Zurawski G., De Vries J.E. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today. 15:1994;19-26.